Cardiopulmonary effects and pharmacokinetics of i.v. dexmedetomidine in ponies.
Authors: Bettschart-Wolfensberger R, Freeman S L, Bowen I M, Aliabadi F S, Weller R, Huhtinen M, Clarke K W
Journal: Equine veterinary journal
Summary
# Editorial Summary: Dexmedetomidine Pharmacokinetics and Cardiopulmonary Effects in Ponies Researchers investigating safer sedative options for equines compared dexmedetomidine (DEX) with existing agents that typically cause substantial cardiopulmonary depression. Eight mature and six aged ponies received intravenous DEX at 3.5 µg/kg, with plasma concentrations and cardiovascular parameters (heart rate, blood pressures, cardiac index, vascular resistance) measured over 60 minutes. Although DEX produced expected alpha-2 agonist effects—transient reductions in stroke volume, cardiac index, and mixed venous oxygen tension alongside increased vascular resistance—these changes resolved within 5–10 minutes, with respiratory rate being the only parameter significantly depressed throughout the observation period; plasma levels fell below detectable thresholds within two hours (half-life: 19.8–28.9 minutes depending on age group). The marked brevity of cardiopulmonary compromise and rapid redistribution kinetics suggest DEX warrants consideration as a safer single-dose sedative for routine procedures, particularly in older animals where prolonged hypotension poses greater risk; however, its short duration and favourable redistribution profile indicate continuous infusion protocols merit investigation for extended sedation requirements rather than repeated boluses.
Read the full abstract on PubMed
Practical Takeaways
- •Dexmedetomidine offers significantly shorter-lasting cardiopulmonary depression compared to other sedatives, making it safer for field sedation of horses with cardiovascular compromise
- •The rapid redistribution profile suggests dexmedetomidine is better suited as a continuous infusion for prolonged sedation rather than single bolus administration
- •Cardiovascular stability is maintained after the initial 5-10 minute period, allowing safe procedures with minimal haemodynamic disturbance
Key Findings
- •Dexmedetomidine 3.5 µg/kg IV has a very short half-life in ponies (19.8 min mature, 28.9 min old) with plasma levels below quantification within 2 hours
- •Heart rate, central venous pressure, pulmonary artery pressure and pulmonary capillary wedge pressure remained stable throughout 60-minute observation period
- •Stroke volume and cardiac index were transiently reduced for only 5-10 minutes respectively, with systemic and pulmonary vascular resistance increasing briefly
- •Respiratory rate was reduced throughout the 60-minute observation but arterial blood gas parameters (PO2 and PCO2) remained unchanged